華海藥業(600521.SH):股東周明華減持期滿 累計減持1464.641萬股
格隆匯 11 月 10日丨華海藥業(600521.SH)公佈,截止2020年11月10日,此次減持計劃時間期滿,股東周明華具體減持情況如下所示:
2020年5月11日至6月5日,周明華通過集中競價方式累計減持公司股份91萬股;
2020年5月21日,公司2019年度利潤分配方案審議通過,即向全體股東每10股派送現金紅利2元,每10股轉增1股。此次2019年度利潤分配方案於2020年6月8日實施完畢;
2020年6月8日至11月10日,周明華通過集中競價方式累計減持公司股份1364.541萬股。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.